Table 2 Literature overview of molecular target guided inclusion in clinical trials in the last five years (from 2016).
Trial | Year published | Design | No° pts included | Type of MDT | Median TAT | % pts with succesful MDT results | % pts with a actionable target | % pts who received matched therapy |
|---|---|---|---|---|---|---|---|---|
Our trial | 2021 | Rare refractory tumour types, matched early-phase clinical trials | N = 31 | WGS | 15 days | 94% (29/31) | 84% (26/31) | 35% (11/31) |
PERMED [29] | 2021 | Refractory tumour types, matched clinical trials/off-label drugs | N = 550 | NGS/aCGH | 58 days [1–645] | 80 (441/550) | 71% (393/550) | 17% (94/550) |
ICT [30] | 2021 | Refractory tumour types, matched off-label drugs based on ctDNA | N = 24 | WGS/NGS | 12 days [IQR 9–14] | 71% (17/24) | 42% (10/24) | 30% (8/24) |
EXOMA [31] | 2020 | Refractory tumour types, off-label drugs | N = 506 | WES | 52 days | 90% (456/506) | 75% (342/456) | 23% (79/342) |
NCI MATCH [32] | 2020 | Refractory tumour types, matched FDA approved/investigational drugs | N = 6391 | NGS | 16 days | 93% (5540/5954) | 38% (2083/5540) | 18% (985/5540) |
WINTHER [33] | 2019 | Refractory tumour types, matched clinical trials/on and off-label drugs | N = 303 | NGS/RNA | Not reported | Not reported | Not reported | 35% (107/303) |
I-PREDICT [20] | 2019 | Refractory tumour types, matched combination therapies; FDA approved/investigational drugs | N = 149 | NGS/IHC | Not reported | Not reported | Not reported | 49% (73/149) |
TARGET [34] | 2019 | Refractory tumour types, matched phase I clinical trials based on ctDNA | N = 100 | NGS ctDNA assay | 33 days [20–80] | 99% (99/100) | 41% (41/100) | 11% (11/100) |
PROFILER [35] | 2019 | Refractory tumour types, prospective MTB guided molecular-based treatment recommendations | N = 2579 | NGS/aCGH | 86 (IQR 63–120) days | 77% (1980/2579) | 40% (1032/2579) | 6% (163/2579) |
IMPACT [21] | 2019 | Refractory tumour types, matched off-label/investigational drugs | N = 3737 | PCR/Sanger | Not reported | 93% (3487/3737) | 51% (1905/3737) | 19% (711/3737) |
CoPPo [19] | 2019 | Refractory tumour types, matched early-phase clinical trials/off-label drugs | N = 591 | WES/RNAseq | 34 days | 92% (460/500) | 70% (352/500) | 20% (101/500) |
Rouven et al. [36] | 2018 | Refractory tumour types, Retrospective MTB guided inclusion in matched clinical trials or off-label drugs | N = 198 | Variable (NGS/WGS/ RNAseq/IHC) | 28 days | Not reported | 53% (104/198) | 32% (33/104) |
MOSCATO-01 [37] | 2017 | Refractory tumour types, matched clinical trials/off-label drugs | N = 1035 | aCGH/NGS/ RNAseq | 21 days [IQR 14–27] | 89% (843/948) | 43% (411/948) | (21%) 199/948 |
Cousin et al. [38] | 2017 | Refractory tumour types, matched phase I clinical trials | N = 568 | NGS | 9 weeks | 95% (540/568) | 51% (292/568) | 15% (86/568) |
